Challenges with the diagnosis and treatment of cerebral radiation necrosis
The incidence of radiation necrosis has increased secondary to greater use of combined
modality therapy for brain tumors and stereotactic radiosurgery. Given that its characteristics …
modality therapy for brain tumors and stereotactic radiosurgery. Given that its characteristics …
The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence
K Parvez, A Parvez, G Zadeh - International journal of molecular sciences, 2014 - mdpi.com
Radiation therapy is an important modality used in the treatment of patients with brain
metastatic disease and malignant gliomas. Post-treatment surveillance often involves serial …
metastatic disease and malignant gliomas. Post-treatment surveillance often involves serial …
[HTML][HTML] A systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and international stereotactic …
B Vellayappan, MJ Lim-Fat, R Kotecha… - International Journal of …, 2024 - Elsevier
Background Radiation necrosis (RN) secondary to stereotactic radiosurgery is a significant
cause of morbidity. The optimal management of corticosteroid-refractory brain RN remains …
cause of morbidity. The optimal management of corticosteroid-refractory brain RN remains …
Differentiation between radiation necrosis and tumor progression using chemical exchange saturation transfer
Purpose: Stereotactic radiosurgery (SRS) is a common treatment used in patients with brain
metastases and is associated with high rates of local control, however, at the risk of radiation …
metastases and is associated with high rates of local control, however, at the risk of radiation …
Distinguishing true progression from radionecrosis after stereotactic radiation therapy for brain metastases with machine learning and radiomics
Purpose Treatment effect or radiation necrosis after stereotactic radiosurgery (SRS) for brain
metastases is a common phenomenon often indistinguishable from true progression …
metastases is a common phenomenon often indistinguishable from true progression …
[HTML][HTML] Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis
P Lohmann, M Kocher, G Ceccon, EK Bauer… - NeuroImage: Clinical, 2018 - Elsevier
Background The aim of this study was to investigate the potential of combined textural
feature analysis of contrast-enhanced MRI (CE-MRI) and static O-(2-[18 F] fluoroethyl)-L …
feature analysis of contrast-enhanced MRI (CE-MRI) and static O-(2-[18 F] fluoroethyl)-L …
Current applications of MRI-guided laser interstitial thermal therapy in the treatment of brain neoplasms and epilepsy: a radiologic and neurosurgical overview
R Medvid, A Ruiz, RJ Komotar… - American Journal …, 2015 - Am Soc Neuroradiology
Minimally invasive stereotactic tumor ablation is a viable option for the treatment of benign
and malignant intracranial lesions. Although surgical excision constitutes first-line therapy …
and malignant intracranial lesions. Although surgical excision constitutes first-line therapy …
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?
A familiar challenge for neuroradiologists and neuro-oncologists is differentiating between
radiation treatment effect and disease progression in the CNS. Both entities are …
radiation treatment effect and disease progression in the CNS. Both entities are …
Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis
Purpose Cerebral radiation necrosis is a complication of radiation therapy that can be seen
months to years following radiation treatment. Differentiating radiation necrosis from tumor …
months to years following radiation treatment. Differentiating radiation necrosis from tumor …
Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery
Purpose We assessed the performance of 6-[18 F]-fluoro-l-3, 4-dihydroxyphenylalanine (F-
DOPA) PET for differentiating radionecrosis (RN) from tumour progression (PD) in a …
DOPA) PET for differentiating radionecrosis (RN) from tumour progression (PD) in a …